GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » EPS without NRI

Genvec (Genvec) EPS without NRI : $-3.66 (TTM As of Mar. 2017)


View and export this data going back to 2000. Start your Free Trial

What is Genvec EPS without NRI?

Genvec's earnings per share without non-recurring items for the three months ended in Mar. 2017 was $-1.88. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2017 was $-3.66.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Genvec's EPS without NRI or its related term are showing as below:

GNVC's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Genvec's EPS (Diluted) for the three months ended in Mar. 2017 was $-1.88. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 was $-3.66.

Genvec's EPS (Basic) for the three months ended in Mar. 2017 was $-1.88. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2017 was $-3.66.


Genvec EPS without NRI Historical Data

The historical data trend for Genvec's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec EPS without NRI Chart

Genvec Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.90 -7.70 -1.60 -3.90 -2.78

Genvec Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.08 -0.60 -0.50 -0.68 -1.88

Competitive Comparison of Genvec's EPS without NRI

For the Biotechnology subindustry, Genvec's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genvec's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Genvec's PE Ratio without NRI falls into.



Genvec EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genvec  (NAS:GNVC) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genvec EPS without NRI Related Terms

Thank you for viewing the detailed overview of Genvec's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Genvec (Genvec) Business Description

Traded in Other Exchanges
N/A
Address
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Executives
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman director 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum director GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky director, officer: President and CEO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins director, officer: President & CEO 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud director
Joshua Ruch director 4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 05-08-2009

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-11-2011

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 08-07-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010